Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPE-791 in Chronic Osteoarthritis Pain or Chronic Low Back Pain
NCT06810245Phase 1Completed
- Sponsor
- Contineum Therapeutics
- Start
- Feb 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PIPE-791 in osteoarthritis (OA) and chronic low back pain (CLBP) (2 arms), sponsored by Contineum Therapeutics. Primary endpoint: Treatment-emergent adverse events at Day 57. Started Feb 2025; status: completed.
02
Drugs
PIPE-791
03
Conditions
osteoarthritis (OA)chronic low back pain (CLBP)
Beyond the preview
Go deeper on NCT06810245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06810245.